Companies who receive scientific advice from our NICE Advice service may experience a faster path to guidance publication, a study has found.

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee C. Committee members are asked to declare any interests in the technology being ...

Elafibranor (Iqirvo) is available on the NHS. It is a possible treatment for primary biliary cholangitis in adults, when used: with ursodeoxycholic acid (UDCA), if the condition has not responded well ...

Review and download supporting evidence. Includes the full guideline if available.

Elafibranor (Iqirvo, Ipsen) is indicated for 'the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as ...

alone, if UDCA cannot be tolerated. Elafibranor is only recommended if the company provides it according to the commercial arrangement.

The evaluation committee considered evidence submitted by Ipsen, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee papers for full ...

This procedure should only be done as part of a formal research study, and a research ethics committee needs to have approved its use.

The appraisal committee has prepared final draft guidance (FDG) on elafibranor for treating primary biliary cholangitis and submitted it to NICE. The FDG has been sent to consultees for this appraisal ...

There is a simple discount patient access scheme for elafibranor. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Evidence-based recommendations on endoscopic bipolar radiofrequency ablation for malignant biliary obstruction. This involves using heat energy to unblock the obstruction. This guidance replaces NICE ...